285 Results

People

  1. Kelsen
    Kelsen
  2. Zelefsky
    Zelefsky
  3. Gralla
    Gralla
  4. Kemeny
    Kemeny
  5. Scher
    Scher
  6. Casper
    Casper
  7. Kollmeier
    Kollmeier
  8. Minsky
    Minsky
  9. Heelan
    Heelan
  10. Ilson
    Ilson

Groups

  1. Department of Medicine (144)
  2. Solid Tumor Oncology Division (114)
  3. Survivorship Research (55)
  4. Gastrointestinal Oncology Service (48)
  5. Center for Pancreatic Cancer Research (41)
  6. Surgery (37)
  7. Hematologic Malignancies, Division of (35)
  8. Radiation Oncology, Department of (32)
  9. Center for Hematologic Malignancies (28)
  10. Genitourinary Oncology Service (28)
  1. "gastrointestinal toxicity"
Formats
  1. Journal Article (272)
  2. Review (4)
  3. Editorial (3)
  4. Research Letter (2)
  5. Conference Paper (1)
  6. Correspondence (1)
  7. Guidelines (1)
  8. Miscellaneous (1)
Groups
  1. Department of Medicine (144)
  2. Solid Tumor Oncology Division (114)
  3. Survivorship Research (55)
  4. Gastrointestinal Oncology Service (48)
  5. Center for Pancreatic Cancer Research (41)
  6. Surgery (37)

More Groups

People
  1. David Kelsen (26)
  2. Michael Zelefsky (23)
  3. Nancy Kemeny (14)
  4. Howard Scher (12)
  5. Richard Gralla (12)
  6. Bruce Minsky (11)

More People

Years
  1. 2025 (4)
  2. 2024 (9)
  3. 2023 (4)
  4. 2022 (3)
  5. 2020 (3)
  6. 2019 (3)

More Years

Publications
  1. Cancer Treatment Reports (27)
  2. Cancer (23)
  3. Journal of Clinical Oncology (21)
  4. International Journal of Radiation Oncology, Biology, Physics (20)
  5. Gynecologic Oncology (9)
  6. Hematology/Oncology Clinics of North America (6)

More Publications

Publishers
  1. Elsevier Inc. (65)
  2. Wiley Blackwell (28)
  3. National Cancer Institute (27)
  4. American Society of Clinical Oncology (21)
  5. Elsevier Science, Inc. (18)
  6. Springer (14)

More Publishers

Results (285)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase I study of panobinostat in children with relapsed and refractory hematologic malignancies
    Journal Article

    Goldberg, J.; Sulis, M. L.; Bender, J.; Jeha, S.; Gardner, R.; Pollard, J.; Aquino, V.; Laetsch, T.; Winick, N.; Fu, C.; more...
    Pediatric Hematology and Oncology (2020)

    Fulltext@MSK | Save
  • Antibody-drug conjugates in prostate cancer
    Miscellaneous

    Danila, D. C.
    Clinical Advances in Hematology & Oncology (2020)

    Fulltext@MSK | Save
  • Immune checkpoint inhibitors: A narrative review of considerations for the anaesthesiologist
    Review

    Lewis, A. L.; Chaft, J.; Girotra, M.; Fischer, G. W.
    British Journal of Anaesthesia (2020)

    Fulltext@MSK | Save
  • High accumulated doses to the inferior rectum are associated with late gastro-intestinal toxicity in a case-control study of prostate cancer patients treated with radiotherapy
    Research Letter

    Casares-Magaz, O.; Bülow, S.; Pettersson, N. J.; Moiseenko, V.; Pedersen, J.; Thor, M.; Einck, J.; Hopper, A.; Knopp, R.; Muren, L. P.
    Acta Oncologica (2019)

    Fulltext@MSK | Save
  • Five-year outcomes of a phase 1 dose-escalation study using stereotactic body radiosurgery for patients with low-risk and intermediate-risk prostate cancer
    Journal Article

    Zelefsky, M. J.; Kollmeier, M.; McBride, S.; Varghese, M.; Mychalczak, B.; Gewanter, R.; Garg, M. K.; Happersett, L.; Goldman, D. A.; Pei, I.; more...
    International Journal of Radiation Oncology, Biology, Physics (2019)

    Fulltext@MSK | Save
  • Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: A randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)
    Journal Article

    Bolaños-Meade, J.; Reshef, R.; Fraser, R.; Fei, M.; Abhyankar, S.; Al-Kadhimi, Z.; Alousi, A. M.; Antin, J. H.; Arai, S.; Bickett, K.; more...
    The Lancet Haematology (2019)

    Fulltext@MSK | Save
  • Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial
    Journal Article

    Guo, J.; Jin, J.; Oya, M.; Uemura, H.; Takahashi, S.; Tatsugami, K.; Rha, S. Y.; Lee, J. L.; Chung, J.; Lim, H. Y.; more...
    Journal of Hematology & Oncology (2018)

    Fulltext@MSK | Save
  • Placement of an absorbable rectal hydrogel spacer in patients undergoing low-dose-rate brachytherapy with palladium-103
    Journal Article

    Taggar, A. S.; Charas, T.; Cohen, G. N.; Boonyawan, K.; Kollmeier, M.; McBride, S.; Mathur, N.; Damato, A. L.; Zelefsky, M. J.
    Brachytherapy (2018)

    Fulltext@MSK | Save
  • Salvage brachytherapy for recurrent prostate cancer after definitive radiation therapy: A comparison of low-dose-rate and high-dose-rate brachytherapy and the importance of prostate-specific antigen doubling time
    Journal Article

    Kollmeier, M. A.; McBride, S.; Taggar, A.; Anderson, E.; Lin, M.; Pei, X.; Weiji, S.; Voros, L.; Cohen, G.; Yamada, Y.; more...
    Brachytherapy (2017)

    Fulltext@MSK | Save
  • Stereotactic body radiation vs. intensity-modulated radiation for unresectable pancreatic cancer
    Journal Article

    Park, J. J.; Hajj, C.; Reyngold, M.; Shi, W.; Zhang, Z.; Cuaron, J. J.; Crane, C. H.; O’Reilly, E. M.; Lowery, M. A.; Yu, K. H.; more...
    Acta Oncologica (2017)

    Fulltext@MSK | Save